Drug intelligence / Profile preview

Zhiling Capsule

Development stage: Unknown
Lead developer: Changxing Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Zhiling Capsule (至灵胶囊) is a Traditional Chinese Medicine (TCM) product developed and manufactured by Zhejiang Changxing Pharmaceutical Co., Ltd. The active ingredient is a fermented mycelium derived from a fungus of the genus *Mortierella*, which was originally isolated from *Cordyceps sinensis* larvae. According to TCM principles, the capsule functions to tonify the lungs and kidneys (补肺益肾). It is primarily indicated for conditions associated with lung-kidney deficiency, such as chronic cough, asthma, and edema. Additionally, it is utilized as an adjunctive therapy for chronic hepatitis, various kidney diseases, and tumors. The product is an approved prescription drug in China with the approval number 国药准字Z33020212.

Brand names: 至灵胶囊
Other names: Zhiling Jiaonang

Beyond the preview

Go deeper on Zhiling Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhiling Capsule.

Explore the full profile